Alessandra Aparecida Paz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alessandra Aparecida Paz has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ana Paula Alegretti
Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil
2 shared publications - Fabrício Figueiró
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
2 shared publications - Liane Esteves Daudt
Universidade Federal do Rio Grande do Sul, Bone Marrow Transplant Department, Porto Alegre, Brazil
2 shared publications - Mariana Bohns Michalowski
Departamento de Pediatria Universidade Federal do Rio Grande do Sul Porto Alegre Brazil
2 shared publications - Alexia N. Sant’aNa
Laboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Brazil
1 shared publication - Alexia Nedel Sant’Ana
Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-003, Brazil
1 shared publication
Latest Publications
- Open Access
LSC-like Phenotypes Aid in the Prognosis of Adult and Elderly Acute Myeloid Leukemia Patients at a Resource-Limited Health Center
Background/Objectives: Relapse is the greatest obstacle in treating acute myeloid leukemia (AML), occurring in 40–50% of younger patients and most elderly patients. Current immunophenotyping panels for diagnosis and detection of measurable residual disease (MRD) primarily focus on detecting blasts, thereby overlooking AML heterogeneity, which could provide valuable prognostic insights. In this context, we propose repositioning EuroFlow panels within a new set of analyses to assess leukemia stem-like phenotypes for AML prognostic monitoring. Methods: We performed a retrospective study with AML patients at the Hospital de Clínicas de Porto Alegre between 2015 and 2023. Results: Our findings highlight the relevance of leukemia stem cell-like phenotypes, particularly the CD123+, CD34+CD123+, and CD34+CD38− subpopulations, for complementary prognostication of adult and elderly patients. A higher percentage of CD123+ cells was a risk factor for both RFS (p = 0.04) and OS (p = 0.02), whereas an increase in CD34+CD123+ cells was a risk factor for RFS (p = 0.04) only. A higher percentage of CD34+CD38− cells was a risk factor for OS (p = 0.002). From diagnosis to the second monitoring, the CD34+ subpopulation was a more relevant prognostic factor in elderly individuals than in adults. CD34&CD38 most immature subpopulations may increase with poor-prognosis markers in both adults and the elderly. Conclusions: Repositioning immunophenotypic analyses may offer a cost-effective alternative for refined prognostication, particularly in healthcare centers that already have flow cytometry-based AML diagnostics.
Open AccessLSC-like Phenotypes Aid in the Prognosis of Adult and Elderly Acute Myeloid Leukemia Patients at a Resource-Limited Health Center
Background/Objectives: Relapse is the greatest obstacle in treating acute myeloid leukemia (AML), occurring in 40–50% of younger patients and most elderly patients. Current immunophenotyping panels for diagnosis and detection of measurable residual disease (MRD) primarily focus on detecting blasts, thereby overlooking AML heterogeneity, which could provide valuable prognostic insights. In this context, we propose repositioning EuroFlow panels within a new set of analyses to assess leukemia stem-like phenotypes for AML prognostic monitoring. Methods: We performed a retrospective study with AML patients at the Hospital de Clínicas de Porto Alegre between 2015 and 2023. Results: Our findings highlight the relevance of leukemia stem cell-like phenotypes, particularly the CD123+, CD34+CD123+, and CD34+CD38− subpopulations, for complementary prognostication of adult and elderly patients. A higher percentage of CD123+ cells was a risk factor for both RFS (p = 0.04) and OS (p = 0.02), whereas an increase in CD34+CD123+ cells was a risk factor for RFS (p = 0.04) only. A higher percentage of CD34+CD38− cells was a risk factor for OS (p = 0.002). From diagnosis to the second monitoring, the CD34+ subpopulation was a more relevant prognostic factor in elderly individuals than in adults. CD34&CD38 most immature subpopulations may increase with poor-prognosis markers in both adults and the elderly. Conclusions: Repositioning immunophenotypic analyses may offer a cost-effective alternative for refined prognostication, particularly in healthcare centers that already have flow cytometry-based AML diagnostics.
- Open Access
- 1 September 2025
- Published by Brazilian Journals in Brazilian Journal of Health Review
- Vol. 8 (5) , e83022
Characterization of very early circulating Natural Killer cells after hematopoietic stem cells transplantation
Natural Killer cells are the first lymphocyte subpopulation to reconstitute after hematopoietic stem cell transplantation. Peripheral blood samples from thirteen patients who underwent allogeneic and autologous hematopoietic stem cell transplantation were analyzed at days 7, 14, 21 and 28 (± 2) after transplantation. Peripheral blood mononuclear cells were isolated using the Bulk Lysis™ EuroFlow standard operating protocol. They were stained for membrane markers with anti-CD45, anti-CD56, anti-CD16, anti-CD3, anti-CD14, anti-CD19, anti-CD2 and anti-CD7; and for intracellular cytokine detection with anti-IL-3, anti-GM-CSF and anti-TGF-1β. On day 7, the presence of Natural Killer cells was detected in 9 patients (mean: 11.6%, SD±: 6.3 of lymphocytes) as well as on day 14 (mean: 16.3%, SD±: 8.2), day 21 (mean: 31.6%, SD±: 9.5) and day 28 (mean: 22.7%, SD±: 6.1). An increase in CD56+16+ phenotype recovery was observed at days 21 (mean: 22%, SD±: 7.2 of lymphocytes, range: 8.0 – 36.1) and 28 (mean: 16%, SD±: 4.9, range: 6.6 – 25.7) when it was compared with CD56bright and CD56+16- (p<0.05). The production of cytokines IL-3, GM-CSF and TGF-β1 was observed during the recovery period of Natural Killer cells within 28 days after transplantation (p=0.04). These data suggest that Natural Killer cells have the ability to produce hematopoietic growth factors and related cytokines which may contribute to the reestablishment of hematopoiesis after transplantation, prevent graft-versus-host disease and enhance the engraftment.
- 1 September 2025
- Published by Brazilian Journals in Brazilian Journal of Health Review
- Vol. 8 (5) , e83022
Open AccessCharacterization of very early circulating Natural Killer cells after hematopoietic stem cells transplantation
Natural Killer cells are the first lymphocyte subpopulation to reconstitute after hematopoietic stem cell transplantation. Peripheral blood samples from thirteen patients who underwent allogeneic and autologous hematopoietic stem cell transplantation were analyzed at days 7, 14, 21 and 28 (± 2) after transplantation. Peripheral blood mononuclear cells were isolated using the Bulk Lysis™ EuroFlow standard operating protocol. They were stained for membrane markers with anti-CD45, anti-CD56, anti-CD16, anti-CD3, anti-CD14, anti-CD19, anti-CD2 and anti-CD7; and for intracellular cytokine detection with anti-IL-3, anti-GM-CSF and anti-TGF-1β. On day 7, the presence of Natural Killer cells was detected in 9 patients (mean: 11.6%, SD±: 6.3 of lymphocytes) as well as on day 14 (mean: 16.3%, SD±: 8.2), day 21 (mean: 31.6%, SD±: 9.5) and day 28 (mean: 22.7%, SD±: 6.1). An increase in CD56+16+ phenotype recovery was observed at days 21 (mean: 22%, SD±: 7.2 of lymphocytes, range: 8.0 – 36.1) and 28 (mean: 16%, SD±: 4.9, range: 6.6 – 25.7) when it was compared with CD56bright and CD56+16- (p<0.05). The production of cytokines IL-3, GM-CSF and TGF-β1 was observed during the recovery period of Natural Killer cells within 28 days after transplantation (p=0.04). These data suggest that Natural Killer cells have the ability to produce hematopoietic growth factors and related cytokines which may contribute to the reestablishment of hematopoiesis after transplantation, prevent graft-versus-host disease and enhance the engraftment.
- 14 December 2024
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 1-15
Prognostic value of myeloid-derived suppressor-like cells in acute myeloid leukemia: insights from immunophenotyping and clinical correlations
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients’ prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45+CD33lowHLA-DR−CD36+ PMN-MDSC-like cells and mature CD13+CD11b+CD10+ neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in FLT3-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML.
- 14 December 2024
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 1-15
Prognostic value of myeloid-derived suppressor-like cells in acute myeloid leukemia: insights from immunophenotyping and clinical correlations
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients’ prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45+CD33lowHLA-DR−CD36+ PMN-MDSC-like cells and mature CD13+CD11b+CD10+ neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in FLT3-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML.
- Open Access
- 14 October 2020
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 1 (3) , 12
COPING WITH THE COVID19 PANDEMIC IN A HEMATOLOGY, TRANSPLANTATION AND CELL THERAPY UNIT IN SOUTHERN BRAZlL
We started 2020 with perspectives that quickly changed in March when the SARS-Cov-2 pandemic started in Brazil. Our center has a unit, called the Protected Environment with 30 beds with HEPA filters where malignant disease, autologous and allogeneic transplants are performed. In March 2020, the contingency plan designed since January to deal with COVID 19 pandemic of Porto Alegre Clinicas Hospital (HCPA) began highly restricting visits, consultations and elective procedures. Our challenge was to maintain the best care for our patients and healthcare professional’s safety. We suspend all visits and reduce relative patients’ companies to only essential. Our team was already one with the highest percentage of hand washing in the hospital, intensified infection control measures and implemented new individual protection equipment surgical masks and face shields. We started a new way to inform family members using digital platforms and improved the Wi-Fi network inside the unit to maintain patient external contact and reduce their loneliness. All Professional meetings and rounds became virtual.1,2,3 When the first cases started in Porto Alegre, we had already implemented and validated the performance of the PCR for SARS-COV-2, with result until 24 hours. So, we could organize the flow of patients for hospitalizations avoiding admissions of Covid asymptomatic patients. HealthCare’s with any symptoms were kept away from work and quickly tested. We followed the guidance of the Brazilian society of BMT and started to perform only urgent transplants, greatly reducing the number of autologous transplants performed. All patients candidates stem cell transplant were instructed to maintain isolation for 14 days before admission and collected PCR 24 hours before admission. Related and unrelated bone marrow donors underwent clinical screening and PCR testing 24 hours before collection and the marrow was cryopreserved until results what changed our routine marrow infusion and sometime modified the collection from marrow to peripheral Hematopoietic stem cell in order to obtain adequate cellularity.1,2,3 Despite all the difficulties and challenges the Covid pandemic imposed upon us, we managed to perform 16 Transplants from March to September, between autologous and allogeneic and we had no cases of covid transmission inside deaths related to COVID until now. All patients who had COVID19 or tested positive to SarsCov2 were outpatients, either from the Day Hospital or the outpatient clinic and had complete resolution of the condition.
- 14 October 2020
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 1 (3) , 12
Open AccessCOPING WITH THE COVID19 PANDEMIC IN A HEMATOLOGY, TRANSPLANTATION AND CELL THERAPY UNIT IN SOUTHERN BRAZlL
We started 2020 with perspectives that quickly changed in March when the SARS-Cov-2 pandemic started in Brazil. Our center has a unit, called the Protected Environment with 30 beds with HEPA filters where malignant disease, autologous and allogeneic transplants are performed. In March 2020, the contingency plan designed since January to deal with COVID 19 pandemic of Porto Alegre Clinicas Hospital (HCPA) began highly restricting visits, consultations and elective procedures. Our challenge was to maintain the best care for our patients and healthcare professional’s safety. We suspend all visits and reduce relative patients’ companies to only essential. Our team was already one with the highest percentage of hand washing in the hospital, intensified infection control measures and implemented new individual protection equipment surgical masks and face shields. We started a new way to inform family members using digital platforms and improved the Wi-Fi network inside the unit to maintain patient external contact and reduce their loneliness. All Professional meetings and rounds became virtual.1,2,3 When the first cases started in Porto Alegre, we had already implemented and validated the performance of the PCR for SARS-COV-2, with result until 24 hours. So, we could organize the flow of patients for hospitalizations avoiding admissions of Covid asymptomatic patients. HealthCare’s with any symptoms were kept away from work and quickly tested. We followed the guidance of the Brazilian society of BMT and started to perform only urgent transplants, greatly reducing the number of autologous transplants performed. All patients candidates stem cell transplant were instructed to maintain isolation for 14 days before admission and collected PCR 24 hours before admission. Related and unrelated bone marrow donors underwent clinical screening and PCR testing 24 hours before collection and the marrow was cryopreserved until results what changed our routine marrow infusion and sometime modified the collection from marrow to peripheral Hematopoietic stem cell in order to obtain adequate cellularity.1,2,3 Despite all the difficulties and challenges the Covid pandemic imposed upon us, we managed to perform 16 Transplants from March to September, between autologous and allogeneic and we had no cases of covid transmission inside deaths related to COVID until now. All patients who had COVID19 or tested positive to SarsCov2 were outpatients, either from the Day Hospital or the outpatient clinic and had complete resolution of the condition.